The molecular diagnostics (MDx) market was worth $6.13bn in 2016 and is estimated to grow at a CAGR of 12.5% from 2017-2021. The fastest growing segment of the molecular diagnostics market over the forecast period 2017-2027 will be the oncology testing segment. The segment was worth $1.08bn in 2016 and represented 17.6% of the molecular diagnostics market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 206-page report you will receive 135 charts – all unavailable elsewhere.
The 206-page report provides clear detailed insight into the molecular diagnostics (MDx) market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• World IVD market forecasts from 2017-2027
• Molecular diagnostics (MDx) market forecasts from 2017-2027
• Revenue and growth forecasts to 2027 for the leading submarkets:
• Infectious Disease Testing
• Oncology Testing
• Blood Screening
• Genetic Testing
• Tissue Typing
• This report provides individual revenue forecasts to 2027 for these regional and national markets:
– US
– Europe:
• Germany
• UK
• Spain
• Italy
• France
• Rest of Europe
– Japan
– China
– Brazil
– Russia
– India
– South Korea
– Mexico
– RoW
• This report discusses the leading companies in the molecular diagnostics (MDx) market:
• Roche Diagnostics
• Qiagen
• Hologic
• Becton, Dickinson & Company
• bioMérieux
• Agilent Technologies
A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Analysis of assays and instruments currently on the market as well as pipeline products
• Acquisitions and strategic partnerships
• This report discusses the SWOT analysis as well as porter’s five forces analysis of the molecular diagnostics (MDx) market
Visiongain’s study is intended for anyone requiring commercial analyses for the molecular diagnostics (MDx). You find data, trends and predictions.
Buy our report today The Molecular Diagnostics (MDx) Market Forecast 2017-2027: Infectious Disease Testing, Oncology Testing, Blood Screening, Genetic Testing, Tissue Typing.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 The Molecular Diagnostics Market Overview
1.2 Molecular Diagnostics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About visiongain
2. Introduction to Molecular Diagnostics
2.1 What are In Vitro Diagnostic (IVD) Tests?
2.2 Classifying In Vitro Diagnostics
2.2.1 FDA Classifications
2.2.2 The EC (European Commission) Classification
2.2.3 IVD Classification in Australia
2.3 IVD Submarkets
2.3.1 Clinical Chemistry
2.3.2 Immunochemistry
2.3.3 Point-of-care Testing (Including Self-Monitoring Blood Glucose Tests)
2.3.4 Molecular Diagnostics
2.3.4.1 Infectious Disease Testing
2.3.4.2 Oncology Testing
2.3.4.3 Blood Screening
2.3.4.4 Genetic Testing
2.3.4.5 Tissue Typing (HLA Testing)
2.3.5 Clinical Microbiology
2.3.6 Haematology/ Haemostasis
2.4 Regulation of the IVD and MDx Market
2.4.1 FDA and CLIA Regulation of IVD and MDx Tests
2.4.2 Regulation of IVD/MDx Tests in the EU: The EC (European Commission) Classification
2.4.3 Top Ten Challenges in Regulation for In-Vitro Diagnostics
2.4.3.1 Challenges in Regulations of MDx Tests
2.5 Device Excise Tax: A Threat to the Diagnostics Manufacturers
3. The Molecular Diagnostics Segment within the In Vitro Diagnostics Market, 2017-2027
3.1 Molecular Diagnostics in the IVD Market, 2016
3.2 Sales Forecast for the Global IVD Market 2017-2027
3.3 Molecular Diagnostics Gaining a Greater Share of the IVD Market
4. The Molecular Diagnostics Market by Sectors, 2017-2027
4.1 The Molecular Diagnostic Market by Sectors, 2016
4.2 The Molecular Diagnostic Market by Sectors 2016-2027
4.2.1 Market Shares of the Molecular Diagnostics Sectors 2016-2027
4.3 The Infectious Disease Testing Market 2016-2027
4.3.1 Breakdown of the MDx Infectious Disease Testing Market by Disease, 2016
4.3.1.1 CT/NG
4.3.1.2 HPV Testing
4.3.1.3 HIV
4.3.1.4 Healthcare Associated Infections (HAI)
4.3.1.5 Hepatitis C (HCV)
4.3.1.6 Respiratory Infections
4.4 The Oncology Testing Market, 2016-2027
4.4.1 Targeted Therapies: A Major Driver of the Oncology Testing Market
4.4.2 Molecular Diagnostics: Currently Concentrated on a Few Cancer Indications
4.4.2.1 Breast Cancer
4.4.2.2 Prostate Cancer
4.4.2.2.1 Prostate Cancer Pipeline Biomarkers
4.4.2.2.1.1 TMPRSS2-ERG (OriGene)
4.4.2.2.1.2 PTEN
4.4.2.3 Colorectal Cancer
4.5 The Blood Screening Market 2016-2027
4.5.1 Grifols’ Acquisition of Novartis’s Blood Screening Unit
4.5.2 Leading Blood Screening Test Products
4.5.2.1 Cobas s 201 System (Roche Molecular)
4.5.2.2 Procleix Assays (Grifols)
4.6 The Genetic Testing Market 2016-2027
4.6.1 Genetic Testing by Clinical Impact Area
4.6.2 Genetic Testing: Potential beyond Oncology
4.6.3 Cystic Fibrosis
4.6.4 Factor V Leiden and Factor II Thrombophilia
4.6.5 Inflammatory Diseases
4.6.5.1 Alzheimer’s Disease (AD)
4.6.5.2 Rheumatoid Arthritis
4.6.5.2.1 Vectra®DA (Crescendo Bioscience)
4.6.5.2.2 Quest Diagnostics: Biomarker Study
4.6.5.3 Rare Diseases
4.7 The Tissue Typing (HLA Typing) Market 2016-2027
4.7.1 Tissue Typing: Next-Generation Sequencing
5. The Leading Molecular Diagnostics National Markets, 2016-2027
5.1 Regional Breakdown of the Global MDx Market, 2016
5.2 The Global MDx Market Forecast, 2017-2027
5.3 The Regional Market Shares of the MDx Market, 2016, 2021 and 2026
5.4 The US MDx Market 2016
5.4.1 The US MDx Market Forecast 2017-2027
5.4.1.1 United States: Diagnostic Reimbursement
5.5 The European MDx Markets Forecast 2017-2027
5.5.1 Changes in the Shares of the Leading European Markets, 2016, 2021 and 2027
5.5.2 Shares of the Major European Markets in a Global Context
5.5.3 The German MDx Market Forecast 2017-2027
5.5.3The French MDx Market Forecast 2017-2027
5.5.4 The Italian MDx Market Forecast 2017-2027
5.5.5 The Spanish MDx Market Forecast 2017-2027
5.5.6 The UK MDx Market Forecast 2017-2027
5.5.7 The Other European MDx Markets Forecast 2017-2027
5.7 Japanese MDx Market Forecast 2017-2027
5.7 The Chinese MDx Market Forecast 2017-2027
5.7.1 China: Increasing Cancer Burden
5.8 The Brazilian MDx Market Forecast 2017-2027
5.9 The Russian MDx Market Forecast 2017-2027
5.10 The Indian MDx Market Forecast 2017-2027
5.10.1 India: Expansion of Healthcare Provisions
5.11 The South Korean MDx Market Forecast 2017-2027
5.12 The Mexican MDx Market Forecast 2017-2027
5.13 The Rest of the World Market Forecast 2017-2027
6. The Leading Companies in the Molecular Diagnostics Market, 2017
6.1 Roche Diagnostics
6.1.1 Roche: Global Presence
6.1.2 Roche Diagnostics, 2016-2027
6.1.3 Roche Diagnostics Business Performance within the IVD Market, 2016
6.1.3.1 Molecular Diagnostics Sales Performance, 2016
6.1.3.2 Molecular Diagnostic Sales by Region, 2016
6.1.4 Roche Diagnostics: MDx Product Launches and Indication Expansion, 2016
6.1.4.1 Roche Diagnostics: Product Launch Plans, 2017
6.1.5 Roche: Major M&A Activity and Strategic Partnerships Strengthen Position as Market Leader
6.1.5.1 Genia Acquisition to Strengthen DNA Sequencing Capabilities
6.1.5.2 IQuum Acquisition Allows Movement into POC MDx Market
6.1.5.3 Seragon Acquisition Strengthens Leading Position in Oncology
6.1.5.4 Santaris Acquisition Enchances Roche’s Position in RNA-Targeted Drugs Market
6.1.5.5 Bina Acquisition Brings Big Data Solution to Support NGS Development
6.1.5.6 Dutalys Acquisition Enhances Roche’s mAB Portfolio
6.1.5.7 Ariosa Acquisition Adds NIPT to MDx Portfolio
6.1.5.8 Foundation Medicine Deal Enhances Personalised Medicine Capabilities for Oncology
6.1.5.9 Signature and CAPP Acquisitions Strengthen Circulating DNA Testing Abilities
6.1.5.10 GENEWEAVE and Kapa Acquisitions Help Cement Roche’s Position as the MDx Market Leader
6.2 Qiagen NV
6.2.1 Sales and Recent Performance Analysis, 2016
6.2.2 Qiagen Sales by Region, 2016
6.2.3 Qiagen Sales by Segment, 2016
6.2.4 Qiagen: Molecular Diagnostics
6.2.5 Molecular Diagnostics: Product Expansion
6.2.5.1 QIASymphony
6.2.5.2 QuantiFERON-TB Gold: Expansion into Asia
6.2.5.3 Personalised Healthcare: Collaborative Efforts
6.2.5.4 Qiagen’s Software Company Acquisitions Cement Leadership in Bioinformatics
6.3 Hologic
6.3.1 Hologic Recent Sales Performance by Business Segment, 2016
6.3.2 Hologic Molecular Diagnostics: Product Portfolio
6.4 Becton, Dickinson and Company
6.4.1 Sales and Financial Performance, 2016
6.4.2 Sales and Financial Performance by Region, 2016
6.4.3 Becton, Dickinson and Company Diagnostics Sales and Financial Performance, 2015-2016
6.4.4 BD Diagnostics: Product Portfolio
6.4.5 BD Diagnostics: Mergers and Acquisitions
6.5 bioMérieux
6.5.1 Sales and Recent Performance Analysis, 2012-2016
6.5.2 Sales by Region, 2016
6.5.3 Sales by Technology, 2016
6.5.4 Molecular Diagnostics: Product Portfolio
6.5.5 Companion Diagnostics: Collaborations with GSK and Novartis
6.5.6 Mergers, Acquisitions and Collaborations
6.5.7 bioTheranostics: Subsidiary for Oncology Diagnostics
6.6 Agilent Technologies
6.6.1 Sales and Recent Performance Analysis, 2016
6.6.2 Sales Performance by Business Segment, 2016
6.6.3 Agilent Technologies: Strong Player in Target Enrichment for Next-Generation Sequencing
7. Qualitative Analysis of the MDx Market, 2017-2027
7.1 MDx Market: Drivers and Restraints
7.2 SWOT Analysis of the MDx Market, 2017-2027
7.2.1 Strengths
7.2.1.1 Patient Demographics
7.2.1.2 Increased Awareness and availibilty of advanced tests
7.2.1.3 High Growth in Oncology Molecular Diagnostics
7.2.1.4 Increasing Laboratory Test Menus
7.2.1.5 Personalised Medicine: Optimising Treatment Outcomes
7.2.2 Weaknesses
7.2.2.1 Lack of Clear Regulatory Guidelines for Molecular Diagnostics
7.2.2.2 Reimbursement Challenges for Molecular Diagnostic Companies
7.2.2.3 Consolidation of Healthcare Systems Increases Pricing Pressure
7.2.2.4 MDx: An Expensive, but Undervalued Diagnostic Tool
7.2.3 Opportunities
7.2.3.1 Next-Generation Sequencing
7.2.3.2 Emerging Markets
7.2.3.3 The Emergence of New Microorganisms
7.2.4 Threats
7.2.4.1 US Medical Device Excise Tax
7.2.4.2 Gene Patents: Controversial Ruling
7.3 Porter’s Five Forces Analysis of the MDx Market
7.3.1 Rivalry among Competitors [High]
7.3.2 Threat of New Entrants [Medium]
7.3.3 Power of Suppliers [Medium]
7.3.4 Power of Buyers [High]
7.3.5 Threat of Substitutes [High]
8. Conclusion
8.1 The Molecular Diagnostics Market: Growing Market Share
8.2 Molecular Diagnostics: Oncology Testing Market Growth
8.3 Commercial Drivers of the Molecular Diagnostics Market
8.4 Commercial Restraints of the Molecular Diagnostics Market
8.5 Emerging Markets
8.6 Concluding Remarks
Appendices
Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
List of Tables
Table 2.1 Advantages and Disadvantages of POC Diagnostics, 2017
Table 3.1 World IVD Market: Revenues ($bn) and Market Share (%) by Segment, 2016
Table 3.2 World IVD Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Segment, 2016-2027
Table 3.3 Market Shares (%) of MDx in the IVD Market, 2016, 2021 & 2027
Table 4.1 The MDx Market: Revenues ($bn) and Market Shares (%) by Segment, 2016, 2021, & 2027
Table 4.2 The Global MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Segment, 2016-2027
Table 4.3 The MDx Market: Market Shares (%) by Segment, 2016, 2021 and 2027
Table 4.4 The Infectious Disease Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 4.5 The Infectious Disease Testing Market: Revenues ($bn) and Market Share (%) by Disease, 2016
Table 4.6 Selected FDA and CE-Approved Molecular Diagnostics Test for CT/NG, 2017
Table 4.7 Selected FDA and CE-Approved Molecular Diagnostics Test for HPV, 2017
Table 4.8 Selected FDA and CE-Approved Molecular Diagnostics Tests for HIV, 2017
Table 4.9 Selected FDA and CE-Approved Molecular Diagnostics Test for HAIs, 2017
Table 4.10 Selected FDA and CE-Approved Molecular Diagnostics Tests for HCV, 2015
Table 4.11 Selected FDA-Approved Molecular Diagnostics Test for Respiratory Infections, 2017
Table 4.12 The Oncology Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 4.13 Examples of Clinically Relevant Cancer Biomarkers Tied with a Drug, 2017
Table 4.14 Selected List of FDA-Approved MDx Tests for Breast Cancer, 2017
Table 4.15 Selected List of FDA-Approved MDx Tests for Prostate Cancer, 2017
Table 4.16 Selected List of FDA-Approved MDx tests for Colorectal Cancer, 2017
Table 4.17 The Blood Screening Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 4.18 The Genetic Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 4.19 Selected Genetic Tests for Cystic Fibrosis on the Market, 2017
Table 4.20 Selected Genetic Tests for Factor V Leiden/Factor II Thrombophilia on the Market, 2017
Table 4.21 Selected Alzheimer’s MDx Diagnostic Tests in Development, 2017
Table 4.22 The Tissue Typing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 4.23 Selected tissue typing Kits on the Market, 2017
Table 5.1 The MDx Market: Revenue ($bn) and Market Share (%) by Region, 2016
Table 5.2 The MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2016-2027
Table 5.3 The MDx Market: Market Shares (%) by Regional Markets, 2016, 2021 and 2027
Table 5.4 The US MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 5.5 The European MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 5.6 The European MDx Market: Market Shares (%) by Country, 2016, 2021 and 2027
Table 5.7 The German MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 5.8 The French MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 5.9 The Italian MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 5.10 The Spanish MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 5.11 The UK MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 5.12 The Other European MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 5.13 The Japanese MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 5.14 The Chinese MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 5.15 The Brazilian MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 5.16 The Russian MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 5.17 The Indian MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 5.18 The South Korean MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 5.19 The Mexican MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 5.20 The Rest of the World MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
Table 6.1 Roche Diagnostics: Revenue ($bn) and Revenue Share (%) by Business Area, 2016
Table 6.2 Roche Molecular Diagnostics: Revenue ($bn), Revenue Shares (%) by Region, 2016
Table 6.3 Roche Diagnostics: Key Product Launches (Instruments/Devices) Planned for 2017
Table 6.4 Roche Diagnostics: Key Product Launches (Tests/Assays) Planned for 2017
Table 6.5 Qiagen: Revenue ($m) and Revenue Share (%) by Region, 2014-2016
Table 6.6 Hologic: Revenue ($bn) and Revenue Share (%) by Segment, 2014-2016
Table 6.7 Becton, Dickinson and Company: Revenue ($bn) and AGR (%) by Region, 2014-2016
Table 6.8 Becton, Dickinson and Company: Sales ($bn), AGR (%) by Life Sciences Segment, 2015-2016
Table 6.9 bioMérieux: Revenue ($bn) and AGR (%), 2012-2016
Table 6.10 bioMérieux: Revenue ($bn) and Revenue Change (%) by Region, 2015-2016
Table 6.11 bioMérieux: Revenue ($bn) and Revenue Share (%) by Region, 2016
Table 6.12 bioMérieux: Revenue ($bn) and Revenue Change (%) by Technology, 2015-2016
Table 6.13 Agilent Technologies: Revenue ($bn) and AGR (%), 2012-2016
Table 6.14 Agilent Technologies: Revenue ($bn) and AGR (%) by Business Segment, 2014-2016
Table 6.15 Agilent Technologies: Revenue ($bn) by Segment, 2014-2016
Table 7.1 SWOT Analysis of the Global MDx Market, 2017-2027
Table 8.1 MDx and Other In Vitro Diagnostics: World Revenue ($bn) Forecast, 2016, 2021 and 2027
List of Figures
Figure 1.1 Molecular Diagnostics: Overview of Submarkets
Figure 3.1 World IVD Market: Revenues ($bn) by Segment, 2016
Figure 3.2 World IVD Market: Revenue Shares (%) by Segment, 2016
Figure 3.3 World IVD Market Forecast: Revenue ($bn) and AGR (%) by Segment, 2016-2027
Figure 3.4 World MDx Market Share (%) in the IVD Market, 2021
Figure 3.5 World MDx Market Share (%) in the IVD Market, 2027
Figure 4.1 The MDx Market Shares (%) by Sector in the IVD Market, 2016
Figure 4.2 The MDx Market: Revenue ($bn) by Segment, 2016
Figure 4.3 The MDx Market: Market Shares (%) by Segment, 2016
Figure 4.4 The Global MDx Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 4.5 The MDx Market: Market Shares (%) by Segment, 2021
Figure 4.6 The MDx Market: Market Shares (%) by Segment, 2027
Figure 4.7 The Infectious Disease Testing Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 4.8 The Infectious Disease Testing Market: Market Shares (%) by Disease, 2016
Figure 4.9 The Oncology Testing Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 4.10 The Cancer Treatment Sequence and the Application of Molecular Diagnostics and Companion Diagnostics
Figure 4.11 The Blood Screening Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 4.12 The Genetic Testing Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 4.13 The Genetic Testing Market by Clinical Impact Area, 2016
Figure 4.14 The Tissue Typing Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 5.1 The MDx Market: Market Shares (%) by Region, 2016
Figure 5.2 The MDx Market: Revenue ($bn) by Region, 2016
Figure 5.3 The MDx Market Forecast: Revenue by Region ($bn), 2016-2027
Figure 5.4 The MDx Market: Market Shares (%) by Region, 2021
Figure 5.5 The MDx Market: Market Shares (%) by Region, 2027
Figure 5.6 The US MDx Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 5.7 The European MDx Market Forecast: Revenue ($bn) by Region, AGR (%), 2016-2027
Figure 5.8 The European MDx Market: Market Shares (%) by Country, 2016
Figure 5.9 The European MDx Market: Market Shares (%) by Country, 2021
Figure 5.10 The European MDx Market: Market Shares (%) by Country, 2027
Figure 5.11 Europe in The Global MDx Market: Market Shares (%) by Country, 2016
Figure 5.12 Europe in The Global MDx Market: Market Shares (%) by Country, 2021
Figure 5.13 Europe in The Global MDx Market: Market Shares (%) by Country, 2027
Figure 5.14 The German MDx Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 5.15 The French MDx Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 5.16 The Italian MDx Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 5.17 The Spanish MDx Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 5.18 The UK MDx Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 5.19 The Other European MDx Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 5.20 The Japanese MDx Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 5.21 The Chinese MDx Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 5.22 The Brazilian MDx Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 5.23 The Russian MDx Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 5.24 The Indian MDx Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 5.25 The South Korean MDx Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 5.26 The Mexican MDx Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 5.27 The Rest of the World MDx Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
Figure 6.1 Roche Diagnostics: Revenues ($bn) by Business Area, 2016
Figure 6.2 Roche Diagnostics: Revenue Share (%) by Business Area, 2016
Figure 6.3 Roche Molecular Diagnostics: Revenue Share (%) by Region, 2016
Figure 6.4 Qiagen:Revenue ($bn), Net Income ($bn) and Profit Margin (%), 2012-2016
Figure 6.5 Qiagen: Revenue ($m) by Region, 2016
Figure 6.6 Qiagen: Revenue Share (%) by Region, 2016
Figure 6.7 Hologic: Revenue ($bn) by Business Segment, 2014-2016
Figure 6.8 Hologic: Revenue Share (%) by Business Segment, 2016
Figure 6.9 Becton, Dickinson and Company: Revenue Share (%) by Segment, 2016
Figure 6.10 Becton, Dickinson and Company: Revenue ($bn) by Region, 2014-2016
Figure 6.11 Becton, Dickinson and Company: Revenue Share (%) by Region, 2016
Figure 6.12 Becton, Dickinson and Company: Revenue Share (%) by Life Sciences Segment, 2016
Figure 6.13 bioMérieux: Revenue ($m) and AGR (%), 2012-2016
Figure 6.14 bioMérieux: Revenue ($bn) by Region, 2016
Figure 6.15 bioMérieux: Revenue Share (%) by Region, 2016
Figure 6.16 bioMérieux: Revenue Share (%) by Technology, 2016
Figure 6.17 Agilent Technologies: Revenue ($bn) and AGR (%), 2012-2016
Figure 6.18 Agilent Technologies: Revenue Share (%) by Business Segment, 2016
Figure 6.19 Agilent Technologies: Revenue Share (%) by Segment, 2016
Figure 7.1 MDx Market: Drivers and Restraints, 2017-2027
Figure 7.2 The Global Over 65 Population: Forecast (millions, AGR%), 2014-2025
Figure 7.3 Porter’s Five Forces Analysis of the MDx Market, 2017-2027
Figure 8.1 MDx and Other In Vitro Diagnostics: World Revenue ($bn) Forecast, 2016, 2021 and 2027
Figure 8.2 Molecular Diagnostics Market Forecast: AGRs (%) in the US, India, China and Global Market, 2016-2027
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
